WASHINGTON, D.C. – August 11, 2015 – The Sabin Vaccine Institute Product Development Partnership (Sabin PDP) has joined The Onchocerciasis Vaccine for Africa (TOVA) Initiative, which was established this year to develop and test a vaccine for onchocerciasis. Also known as river blindness, onchocerciasis infects an estimated 17 million people, with more than 99 percent of these cases spread throughout 31 countries in sub-Saharan Africa. Approximately 169 million people are at risk of contracting this disease.
LONDON — July 30, 2015 — Sabin Foundation Europe (SFE), the UK partner of the Sabin Vaccine Institute (Sabin), today announced the election of Ms. Cecile Hillary, managing director at Morgan Stanley and co-head of debt capital markets for financial institutions in Europe, to the SFE Board of Trustees.
WASHINGTON DC – JULY 27, 2015—A study titled “Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease” (Hadinegoro et al.), published today in The New England Journal of Medicine, assesses vaccine efficacy and interim long-term safety results of Sanofi Pasteur’s dengue vaccine candidate, CYD-TDV, across three clinical trials in dengue-endemic countries within Asia-Pacific and Latin America. This analysis marks a significant scientific milestone in Sanofi Pasteur’s efforts to develop a dengue vaccine.
WASHINGTON, DC – July 24, 2015 – The Dengue Vaccine Initiative (DVI) a consortium comprised of the International Vaccine Institute, the Johns Hopkins University’s International Vaccine Access Center, Sabin Vaccine Institute and the World Health Organization, is delighted to announce the appointment of Dr. In-Kyu Yoon as its new Director. Dr. Yoon, former Chief of the Department of Virology, Armed Forces Research Institute Medical Sciences in Bangkok, Thailand, will lead DVI starting August, 2015.
WASHINGTON, D.C. — July 13, 2015 — The Sabin Vaccine Institute (Sabin) today released updates on its product development partnership (Sabin PDP) and five Phase 1 clinical trials for two vaccine candidates for human hookworm, one of the most common neglected tropical diseases (NTDs).
WASHINGTON, D.C. — June 3, 2015 — The Sabin Vaccine Institute Product Development Partnership (Sabin PDP) today released an update on a Phase 1 clinical trial of its vaccine candidate to prevent intestinal schistosomiasis, Sm-TSP-2/Alhydrogel®. Schistosomiasis is one of the most pervasive neglected tropical diseases (NTDs) affecting the world’s poorest communities. The Sabin PDP is based at the Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development at Baylor College of Medicine (BCM) in Houston, Texas.
BALI, INDONESIA — May 1, 2015 —The Coalition against Typhoid (CaT), in collaboration with Bio Farma, began the 9th International Conference on Typhoid and Invasive NTS Disease in Bali, Indonesia, with more than 200 public health experts from around the world in attendance. Over the next three days, they will discuss strategies to combat typhoid and invasive non-typhoidal salmonella (iNTS) disease. Experts will present their research on disease burdens, the cost effectiveness of intervention strategies and global policy recommendations for invasive salmonelloses.
WASHINGTON, D.C. — April 15, 2015 — The Sabin Vaccine Institute (Sabin) presented the 2015 Albert B. Sabin Gold Medal Award to Roger I. Glass, MD, PhD, director of the Fogarty International Center and associate director for international research at the National Institutes of Health. Dr. Glass was recognized for his many contributions to improving children’s health worldwide, including novel scientific research for the prevention of gastroenteritis from rotaviruses and noroviruses.
LONDON – April 7, 2015 – Sabin Foundation Europe, the UK partner of the Sabin Vaccine Institute (Sabin), today announced the appointment of Mr. John Cummins, Group Treasurer of the Royal Bank of Scotland, as chairman of Sabin Foundation Europe (SFE), and the election of Rt Hon Baroness Helene Hayman GBE, a member of the UK Parliament’s House of Lords, to the SFE Board of Trustees. Mr. Cummins has served on the SFE Board of Trustees since January 2013. Baroness Hayman has served on the Sabin Board of Trustees since July 2011 and will continue to do so as she joins the SFE Board.
WASHINGTON, D.C. — March 25, 2015 — The Sabin Vaccine Institute (Sabin) will present the Albert B. Sabin Humanitarian Award to Gary Michelson, MD, a distinguished orthopedic spinal surgeon and inventor, in recognition of his extraordinary philanthropy and commitment toward the control and elimination of neglected tropical diseases (NTDs) through high-level advocacy and vaccine research and development. He will be honored today at a private event with Sabin’s executive leadership, Board of Trustees and key members of the scientific community in Houston, Texas.